MESOX has been prominently featured in the International Biopharmaceutical Industry journal. The article, titled “Are We Ready to Formulate the Next Generation of Small Targeted Therapeutics?”, highlights the company’s revolutionary MesoPAC carrier as a key solution for the unique challenges presented by emerging drug modalities like PROTACs.
The article emphasizes the growing importance of overcoming formulation challenges, such as poor solubility and bioavailability, faced by these novel therapeutics. MESOX’s MesoPAC carrier, engineered from an FDA-approved cellulose derivative, offers a groundbreaking approach to enhance drug dissolution and stability, paving the way for greater therapeutic effectiveness.
The publication details the carrier’s success in formulating complex molecules, including PROTACs, and underscores its potential to accelerate the development of targeted therapies, ultimately leading to improved patient outcomes. This recognition in a leading industry journal solidifies MESOX’s position in drug delivery and showcases the transformative potential of its nanopore carrier technology. For references, the written publication by MESOX is featured on pages 22-23 of Volume 6, Issue 2 of the IBI Journal.
